RxDoctor Payments Data

Preti Chaturvedi, MD

Nephrology · Akron, OHNPI 1497860365

Payments from drug & device makers

$10,682in general payments, 2019–2025

Across 315 payments — averaging $33.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$4K
  • Amgen$2K
  • Mallinckrodt Hospital Products Inc.$673
  • AstraZeneca$631
  • Otsuka America Pharmaceutical, Inc.$494
  • Vifor Pharma, Inc.$469
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$2,95028%
  • Travel & lodging$8288%
  • Food & beverage$6,28559%
  • Education$6196%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,682 in reported general payments places this provider in the 80th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$86,411
Medicare patients
234
Services billed
705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol78$61,578
JardianceEmpagliflozin23$17,042
KerendiaFinerenone18$11,178
LokelmaSodium Zirconium Cyclosilicate14$8,738
Sevelamer Carbonate31$2,359
Calcitriol41$806
Allopurinol73$650
Furosemide74$430
Losartan Potassium56$312
Lisinopril39$304
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide36$265
Chlorthalidone18$232
Potassium Chloride17$139
Spironolactone28$125
Hydrochlorothiazide28$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$631$70,31792 claims
Boehringer IngelheimJardiance$27$17,04223 claims
BayerKerendia$101$11,17818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 nephrology providers in Ohio.

Other nephrology in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →